One-Liner
A workflow platform that automates the re-consenting, IRB amendment filing, and electronic trial master file migration work that happens when a biotech acquirer inherits active clinical trials from an acquired company.
AI Thinking Process
Signal 11: Zymeworks bought Theravance, Ipsen bidding for Kartos + Memo Therapeutics. Acquirer inherits 3-15 active clinical trials with distinct IRB approvals, CRO contracts, patient consent forms tied to legal sponsor name. 6-12 months of re-consenting and eTMF migration per M&A close.
Halloran Consulting, ClinChoice, PPD (Thermo Fisher), Deloitte life-sciences M&A — all occupy at $200-500K/engagement. Halloran hasn't shipped software. Veeva ships eTMF migration tools but not managed integration. G200 live-test: Parexel-Palantir 2025 partnership flagged as adjacent.
Sell to CROs directly rather than acquirer. CROs get paid to do integration for pharma clients. But G200 fired: Parexel-Palantir 2025 partnership on similar shape. CROs are prime AI-vendor partnership targets.
Conviction 36% — survived Pass 1 but flagged as borderline. G200 concern needs Pass 2 web-verify. Consulting-as-insurance buyer identity is a real risk. TAM borderline ($6-15M pure-software).
Zymeworks/Theravance and Ipsen/Kartos-Memo M&A cross-verified. 6-12 month integration timelines cross-verified (Halloran case studies + Applied Clinical Trials). 20-30 biotech M&A/year with late clinical portfolios cross-verified (BioPharma Dive). Consulting price band $200-500K is single-source only.
Parexel-Palantir 2025 strategic collaboration confirmed adjacent. Veeva Vault Professional Services has migration utilities. Medidata and Oracle could add M&A workflow as add-on. Competitor closure horizon: 12-18 months. No funded startup in biotech M&A trial integration workflow specifically — gap still open but narrowing.
KILLED IN DEEPENING: G200 competitor-closure clock (Parexel-Palantir + Veeva + Medidata adjacent surface) + consulting-buyer identity capping software pricing + cyclical M&A-dependent revenue = revised conviction 28%, below 30% Pass 2 threshold. Kill confirms G200 validation in painpoint flavor.
Kill Reason
The competitor closure clock is closing within 12-18 months. Parexel entered a strategic AI collaboration with Palantir in April 2025 directly adjacent to this workflow. Veeva Vault has eTMF migration utilities that extend toward managed integration. Medidata and Oracle Health Sciences could ship M&A migration workflow as an add-on. The consulting-buyer identity (VP Clinical Ops who values the 'insurance policy' of a name-brand consulting firm) caps software-only pricing. Cyclical M&A-dependent revenue adds volatility below the $10M ARR threshold at pure-software pricing.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.